Factors released from human breast-cancer cells counteract the inhibitory effects of mevinolin on DNA-synthesis and morphology but not on hmg coa reductase-activity.
Treatment with mevinolin (an HMG CoA reductase inhibitor) blocks proliferation and causes characteristic morphological changes in human breast cancer cells (MDA231). In this study we demonstrate that the conditioned medium of these cells contains factors that stimulate DNA synthesis and normalize morphology in mevinolin-treated cells, without reducing the inhibition of HMG CoA reductase activity. These data suggest that the breast cancer cells produce and release mevalonate-derived products which influence DNA synthesis and morphology. By undertaking a simple purification of the conditioned medium we could demonstrate that the effects on DNA synthesis and morphology were mediated by different compounds.